COVAXIN - India's First indigenous COVID-19 Vaccine

COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.

The Drugs Controller General of India (DCGI) approved Covaxin, which was developed locally by Hyderabad-based Bharat Biotech International Ltd. in collaboration with the Indian Council of Medical Research, and is still in phase III trials.

The placebo-controlled, double-blinded clinical trial to evaluate the safety and immunogenicity of the vaccine enrolled approximately 375 participants.

Of these, 300 subjects received the vaccine doses while 75 subjects received the placebo. Participants received two intramuscular doses of vaccine on day 0 (baseline) and day 14.


Doctors Liked to Read More

Interim data showed that on day 28, all participants who received the vaccine had significantly elevated Spike binding IgG antibodies and neutralising antibody titers.

The vaccine-induced antibody responses and could potentially neutralise both homologous (vaccine virus strain) and heterologous (divergent) SARS-CoV-2 strains.

Bharat Biotech’s Covid-19 vaccine shows no serious adverse effects in trial

Indian firm Bharat Biotech has reported interim results from the Phase I clinical trial that showed its Covid-19 vaccine, COVAXIN (BBV152), induced a robust immune response with no serious adverse effects.

The vaccine, stored between 2°C and 8°C, is ideal for all national immunisation programme cold chain needs, Bharat Biotech noted.

“Permission for restricted use in clinical trial mode has been allowed which means consent of participants has to be taken and there has to be a regular follow up of participants”.

https://www.bharatbiotech.com/covaxin.html

https://www.pharmaceutical-technology.com/news/bharat-biotech-covaxin-trial/



This is for informational purposes only. You should consult your clinical textbook for advising your patients.